Colleagues, Partners & Friends,
As we look forward to seeing many of you at the 2026 Alzheimer’s Association International Conference in London, I look back with pride on the Global Alzheimer’s Platform Foundation’s (GAP) Q2 performance.
Our Trial Execution Services (TES) (GAP Participant Services and Inclusive Research Initiative®) teams collectively supported 120 GAP-Net site events that resulted in nearly 850 individuals screened for a GAP-enabled trial. The creativity in their engagement approaches remain the heart of our successes.
Across North America, we have significantly increased awareness, education, and access to blood-based biomarker (BBM) diagnostic tests for Alzheimer’s disease through our healthcare provider engagement program, CNS Insights Collaborative. In just three months, we have connected with more than 570 healthcare providers, equipping clinics with the knowledge and resources to support the use of p-tau181 & p-tau217 BBMs and enhance patient care.
Both arms of the Bio-Hermes study continue to advance and redefine the Alzheimer’s disease landscape, generating critical insights that are shaping the future of diagnosis, treatment, and care. On July 31st, it will be one year since the Bio-Hermes-001 data was made publicly available and we have approved more than 206 requests for access to the dataset. This robust dataset has supported the FDA applications of multiple BBM diagnostic tests as well as promising digital cognitive tests that offer catalytic changes to how we conduct clinical trials and clinical care. We have reinforced these developments in a number of conversations with TrialSite News.
Our team is hyper focused on closing the enrollment of our Bio-Hermes-002 biomarker study which is set for the end of July; the cross-sectional phase of the study will be finished in Q4, and data lock will occur in February 2027.
This study builds on the Bio-Hermes-001 dataset. The breadth and depth of the Bio-Hermes-002 study continues to gain additional partners including Circular Genomics, Sanofi, Siemens Healthineers, and Taudia, demonstrating the need for large, well characterized, multimodal data that will support the validation of next generation technologies. Gold standard amyloid and Tau PET scans in combination with novel digital and blood-based biomarkers, multi-omics, and a state-of-the-art set of MRI sequences ensures that the analysis of the cohorts is as encompassing as the field currently allows. This study includes over 1,000 participants, nearly 30% of those participants being from understudied populations (USP), and 12 and 24 month-long sub-studies that will be a guidepost for its next iteration.
The needs of patients and trial participants have been, and will continue to be, the center of our work. Their perspective is vital to the development and creation of clinical trials, which is something I reiterated in a White Paper in collaboration with Bristol Myers Squibb.
Early data from Bio-Hermes-002 will be presented in a poster we are proud to provide in: ‘A Comparison of Flortaucipir and MK6240 Tau PET Positivity Rates in the Bio-Hermes-002 Study’ (Poster Number: Sunday-0978, Exhibit Hall 12July2026). In addition,GAP’s Assistant Vice President of Trial Execution Services, Dr. Tamiko MaGee-Rodgers, is an author, along with members of her Inclusive Research Initiative® team, on a Roche poster, ‘Expanding Clinical Trial Access to Underrepresented Populations in the U.S.: Findings from the Alzheimer’s Disease Pre-Screener Study’ (Abstract #5402, Exhibit Hall 12July2026).
Many of our friends and partners have inquired about the location of our 2027 GAP-Net Site Optimization Conference and I am pleased to announce that it will be held in Atlanta, Georgia from March 1st through 3rd, 2027. In a state with nearly 200,000 people living with Alzheimer’s and a multi-cultural capital city, we anticipate great discussions to come during our time there. Further details on sponsorship and registration pricing will be shared soon.
If you are eager to hear from us before Atlanta, please attend our third annual Inclusive Research Initiative virtual conference on November 12, 2026. This half-day, free conference is led by our IRI team to accelerate, advance, and advocate for increased diversity in all aspects of clinical research. I encourage you to look back at last year’s highly attended panels featuring speakers from major universities and small-town research sites, trial participants, lifelong researchers, educators and advocates as they explored cultural, financial, governmental, and medical barriers to participation in clinical trials, and shared actionable strategies to overcome them.
Already halfway through 2026 and GAP is amping up for a rigorous, vigorous remaining six months. We are grateful for the opportunity to do the work.
Regards,
John Dwyer
President